These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Association between folate-metabolizing pathway polymorphism and non-Hodgkin lymphoma.
    Author: Kim HN, Lee IK, Kim YK, Tran HT, Yang DH, Lee JJ, Shin MH, Park KS, Shin MG, Choi JS, Kim HJ.
    Journal: Br J Haematol; 2008 Feb; 140(3):287-94. PubMed ID: 18042267.
    Abstract:
    Polymorphisms in the genes coding folate-metabolizing enzymes affect the risk of some forms of cancer. We investigated the association between these polymorphisms and non-Hodgkin lymphoma (NHL) risk in a population-based study (583 cases and 1700 controls). The MTHFR 677TT and CT genotypes were associated with reduced risk for NHL [odds ratios (OR) = 0.79; 95% confidence intervals (CI) = 0.65-0.98 for 677CT and 0.61; 0.45-0.82 for 677TT] and diffuse large B-cell lymphoma (DLBCL) (OR = 0.68; 0.51-0.88 for 677CT; OR = 0.56; 0.38-0.83 for 677TT). The MTHFR 1298CC genotype was associated with increased risk for NHL (OR = 1.71; 1.07-2.75) and T-cell lymphoma (OR = 3.05; 1.53-6.11). The MTRR 66GG genotype was associated with increased risk for DLBCL (OR = 1.56; 1.03-2.38) and the TYMS 2R2R genotype was associated with increased risk for T-cell lymphoma (OR = 2.83; 1.33-6.01). Using subjects with 3RG3RG as a reference group, TYMS 2R2R was associated with increased risk for T-cell lymphoma (OR = 2.46; 1.04-5.79). Interestingly, we observed a reduced association between the TYMS 2R3RG genotype and DLBCL (OR = 0.61; 0.38-0.99). These results suggest that MTHFR, MTRR and TYMS polymorphisms may play a significant role in the risk for NHL.
    [Abstract] [Full Text] [Related] [New Search]